Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of “Moderate Buy” by Analysts
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among […]
More Stories
Andre Agassi Wins His Professional Pickleball Debut With Partner Anna Leigh Waters
By The Associated Press NAPLES, Fla.—Andre Agassi won his professional pickleball debut a day after turning 55, teaming with 18-year-old...
Market Review: Stocks Retreat on Fed Caution and Trade Uncertainty
By Panos Mourdoukoutas U.S. stocks edged slightly lower this week, ending a nine-day winning streak that pushed the S&P 500...
India and Pakistan Agree to US-Mediated Cease-Fire
By Andrew Thornebrooke India and Pakistan have agreed to the terms of a U.S.-mediated cease-fire following three days of cross-border...
FDA Approves 3 Natural Color Additives Amid Push to Remove Artificial Food Coloring
By Bill Pan The U.S. Food and Drug Administration (FDA) has approved three color additives derived from natural sources for...
Google to Pay $1.4 Billion to Texas, Settle Data Privacy Case
By Naveen Athrappully Google has agreed to settle multiple data privacy lawsuits brought by Texas Attorney General (AG) Ken Paxton...
Ukraine and Allies Call on Russia to Accept US Cease-Fire Proposal
By Andrew Thornebrooke Ukraine and its international partners are calling on Russia to accept a U.S. proposal for a “full,...